Cholesterol (and cardiovascular risk) in adolescence

Current Opinion in Pediatrics

Volumn 16, Issue 4, 2004, Pages 357-362

  Kohn, Michael ^a,b   Jacobson, Marc S ^b,c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b SCHNEIDER CHILDREN'S HOSPITAL   (United States)

^c CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

Author keywords

Adolescents; Cardiovascular risk; Cholesterol

Indexed keywords

ATORVASTATIN; CHOLESTEROL; CORTICOSTEROID; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HOMOCYSTEINE; ISOTRETINOIN; MEVINOLIN; NEUROLEPTIC AGENT; NICOTINIC ACID; SIMVASTATIN;

ANAMNESIS; ATHEROSCLEROSIS; BLOOD GROUP; BODY FAT; BODY MASS; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; GENETICS; GENOTYPE; HUMAN; HYPERLIPIDEMIA; LIFESTYLE; MEDICAL RESEARCH; MEDICAL SPECIALIST; METABOLIC SYNDROME X; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIDE EFFECT;

ADOLESCENT; ANTICHOLESTEREMIC AGENTS; ARTERIOSCLEROSIS; CHOLESTEROL; HUMANS; LOVASTATIN; OBESITY; RISK FACTORS; SIMVASTATIN;

EID: 3442901647     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mop.0000133629.49167.3f     Document Type: Review

References (34)

1. McGill HC Jr, McMahan CA, Zieske AW, et al.: Associations of coronary heart disease risk factors with the intermediate lesion of atherosclerosis in youth: the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Arterioscler Thromb Vasc Biol 2000, 20:1998-2004.
2. Berenson GS, Srinivasan SR, Bao W, et al.: Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults: the Bogalusa Heart Study. N Engl J Med 1998, 338:1650-1656.
3. McGill HC Jr, McMahan CA: Starting earlier to prevent heart disease. JAMA 2003, 290:2320-2322.
4. Katchadurian AK, Uthman SM: Experiences with the homozygous cases of familial hypercholesterolemia: a report of 52 patients. Nutr Metab 1973, 15:132-140.
5. Harada-Shiba M, Takagi A, Miyamoto Y, et al.: Clinical features and genetic analysis of autosomal recessive hypercholesterolemia. J Clin Endocrin Metab 2003, 88:2541-2547.
6. Garcia Ck: Wilund K, Arca M, et al. Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adapter protein. Science 2001, 292:1394-1398.
7. Lemiux I, Pascot A, Couillard C, et al.: Hypertriglyceridemic waist: a marker of atherogenic metabolic triad (hyperinsulinism; hyperapolipoprotein B; small, dense LDL) in men? Circulation 2000, 102:179-184.
8. National Center for Health Statistics: Plan and operation of the Third National Health and Examination Survey, 1988-1994. 1994, http//www.cdc. gov/nchs/data/series/sr_01/sr01_032.pdf.
9. Kahn HS, Valdez R: Metabolic risks identified by the combination of enlarged waist and elevated triacylglycerol concentration. Am J Clin Nutr 2003, 78:928-934. A population-based cross-sectional study identifying the utility of measuring waist circumference as an indicator of cardiovascular risk. Increasing abdominal girth (above 95 cm for men and 88 cm for women) was shown to correlate with age and metabolic risk.
10. Zhu S, Wang Z, Heshka S, et al.: Waist circumference and obesity associated risk factors among whites in the third National Health and Nutrition Survey: clinical action thresholds. Am J Clin Nutr 2002, 76:743-749.
11. Bacha F, Saad R, Gungor N, et al.: Obesity, regional fat distribution, and syndrome X in obese black versus white adolescents: race differential in diabetogenic and atherogenic risk factors. J Clin Endocrinol Metab 2003, 8:2534-2540.
12. Cruz ML, Weigensberg MJ, Huang TT, et al.: The metabolic syndrome in overweight Hispanic youth and the role in insulin sensitivity. J Clin Endocrinol Metab 2004, 89:108-113. This study demonstrates that insulin resistance is independently related to adverse lipid profile, blood pressure, and abdominal obesity.
13. Vgontzas AN, Bixler EO, Chrousos GP: Metabolic disturbances in obesity versus sleep apnea: the importance of visceral obesity and insulin resistance. J Intern Med 2003, 254:32-44.
14. Oren A, Vos LE, Uiterwaal CS, et al.: Change in body mass index from adolescence to young adulthood and increased carotid intima-media thickness at 28 years of age: the Atherosclerosis Risk in Young Adults study. Int J Obes Relat Metab Disord 2003, 27:1383-1390. This study confirms the tracking of BMI and concomitant increase in CIMT, and importantly the reversal of these changes for those members of the cohort with decreasing BMI through adolescence.
15. Vos LE, Oren A, Uiterwaal C, et al: Adolescent blood pressure and blood pressure tracking into young adulthood are related to subclinical atherosclerosis: the Atherosclerosis Risk in Young Adults (ARYA) study. Am J Hypertens 2003, 16:549-555.
16. Vos LE, Oren A, Bots ML, et al.: Does a routinely measured blood pressure in young adolescence accurately predict hypertension and total cardiovascular risk in young adulthood? J Hypertens 2003, 21:2027-2034. The findings of this study strengthen the concept that elevated blood pressure in adolescence unfavorably affects cardiovascular risk, as indicated by increased CIMT.
17. Li SC, Chen W, Srinivasan S, et al.: Childhood cardiovascular risk factors and carotid vascular changes in adulthood: the Bogalusa Heart Study. JAMA 2003, 290:2271-2276.
18. Raitakari OT, Juonala M, Kähönen M, et al.: Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood: the Cardiovascular Risk Study in Young Finns. JAMA 2003, 290:2277-2283.
19. Glowinska B, Urban M, Koput A, et al.: New atherosclerosis risk factors in obese, hypertensive and diabetic children and adolescents. Atherosclerosis 2003, 167:275-286. In this study the levels of "new" cardiovascular risk factors (lipoprotein a, apolipoproteins A-1 and B, homocysteine, fibrinogen, and tissue plasminogen activator) are measured in children and adolescents with "traditional" risk factors (obesity, hypertension, and diabetes)
20. Knoflach M, Kiechl S, Kind M, et al.: Cardiovascular risk factors and atherosclerosis in young males: ARMY study (Atherosclerosis Risk-factors in Male Youngsters). Circulation 2003, 108:1064-1069. This cohort study describes the tracking of atherosclerotic changes from the first decades of life and promotes the concept of immune reactivity as a cardiovascular risk factor.
21. Vgontzas AN, Bixler EO, Chrousos GP: Metabolic disturbances in obesity versus sleep apnea: the importance of visceral obesity and insulin resistance. J Intern Med 2003, 254:32-44. This study identifies that obstructive sleep apnea is independently linked to both the metabolic syndrome and abdominal obesity.
22. Tonstad S, Refsum H, Ueland PM: Association between plasma total homocysteine and parental history of cardiovascular disease in children with familial hypercholesterolemia. Circulation 1997, 96:1803-1808.
23. Van den Bosch MA, Bloemenkamp DG, Mali WP, et al.: Hyperhomocysteinemia and risk for peripheral arterial occlusive disease in young women. J Vasc Surg 2003, 38:772-778.
24. Deleted in proof.
25. American Academy of Pediatrics: Committee on Nutrition Cholesterol in Childhood. Pediatrics 1998, 101:141-147.
26. The Writing Group for the DISC Collaborative Research Group: Efficacy and safety of lowering dietary intake of fat and cholesterol in children with elevated low-density lipoprotein cholesterol. JAMA 1995, 273:1429-1435.
27. Obarzanek E, Hunsberger SA, Van Horn L, et al.: Safety of a fat-reduced diet: the Dietary Intervention Study in Children (DISC). Pediatrics 1997, 100:51-59.
28. Jacobson MS, Tomopoulos S, Williams CL, et al.: Normal growth in high risk hyperlipidemic children and adolescents with dietary Intervention. Prev Med 1998, 27:775-780.
29. Engler MM, Engler MB, Malloy MJ, et al.: Antioxidant vitamins C and E improve endothelial function in children with hyperlipidemia: Endothelial Assessment of Risk from Lipids in Youth (EARLY) Trial. Circulation 2003, 108:1059-1063. This randomly controlled trial is the first to show a long-term effect of vitamin E and vitamin C supplementation on physiologic measures of early atherosclerosis in adolescents. It is well designed and implemented.
30. Sanchez-Bayle M, Soriano-Guillen L: Influence of dietary intervention on growth in children with hypercholesterolemia. Acta Paediatr 2003, 92:1043-1046. This trial shows impressive lipid results of TLC in pediatric practice.
31. Stein EA, Illingworth DR, Kwiterovitch PO, et al.: Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia. JAMA 1999, 281:137-144.
32. de Jongh S, Ose L, Szamosi T, et al.: Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin. Circulation 2002, 106:2231-2237.
33. Dirisamer A, Hachemian N, Bucek RA, et al.: The effect of low-dose simvastatin in children with familial hypercholesterolaemia: a 1-year observation. Eur J Pediatr 2003, 162:421-425. Well-controlled study with dose-response data.
34. McCrindle BW, Ose L, Marais AD: Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial. J Pediatr 2003, 143:74-80. Most recent large trail of a statin widely prescribed for adults, showing impressive LDL-C lowering effects over a 12-month period with minimal adverse events: a well-designed and well-executed study.